MYRIAD GENETICS, INC. Contract with Customer, Refund Liability
MYRIAD GENETICS, INC. (MYGN) had Contract with Customer, Refund Liability of $2.20 million as of 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerRefundLiability · last filed 2020-11-09
- 2020-09-30: Contract with Customer, Refund Liability $2.20M.
| Period end | Contract with Customer, Refund Liability |
|---|---|
| 2020-09-30 | $2.20M 10-Q · filed 2020-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |